Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors

Trial Profile

A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors

Phase of Trial: Phase I/II

Latest Information Update: 10 Dec 2018

At a glance

  • Drugs Avelumab (Primary) ; Regorafenib (Primary)
  • Indications Biliary cancer; Carcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Oesophageal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REGOMUNE
  • Most Recent Events

    • 05 Jun 2018 Trial design was presented at 54th Annual Meeting of the American Society of Clinical Oncology.
    • 01 Jun 2018 Status changed from not yet recruiting to recruiting.
    • 26 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top